With a Brexit deal still out of sight, there have been intensified warnings in the UK about potential disruptions to medicine supplies that could follow a no-deal scenario.
Just a few months after Immune Design saw its shares crater on a phase II fail, Merck & Co/MSD has agreed a deal to acquire the biotech and its immuno-oncology and vaccines pipeline.
Roche has announced that the FDA has granted Priority Review to two of its drugs – personalised lung cancer medicine entrectinib and lymphoma treatment polat
Roche has finally won NICE backing for the use of Perjeta (pertuzumab) to prevent early-stage HER2-positive breast cancer from recurring after surgery, at the third attempt.
The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies' pipelines as they tighten their focus on the projects with the most chance of a
While the controversy surrounding Vertex Pharma’s cystic fibrosis drug in the UK grows more intense, the US firm has announced that it is licensing back two gene editing compounds that can
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.